HealthEquity (HQY) traded higher Friday, up 3.46% to $80.58, as buyers leaned into the company’s improved forward outlook and profitability narrative that was set in motion with its fiscal fourth-quarter and full-year results released March 17, 2026. In that report, HealthEquity highlighted record results and raised its fiscal 2027 guidance, citing strong HSA sales and material margin expansion.

In the March 17, 2026 release, HealthEquity reported fiscal-year revenue of $1.31 billion (up 9%) and net income of $215.2 million, or $2.46 per diluted share, alongside non-GAAP net income per diluted share of $4.00. The company also pointed to expanding profitability (adjusted EBITDA margin) and scale in its core franchise, ending fiscal 2026 with 17.8 million total accounts and more than $36 billion in HSA assets—metrics that can matter for recurring fee revenue and custodial economics as rate expectations shift.

Separately, investors have had fresh corporate developments to digest in recent weeks. On March 30, 2026, HealthEquity disclosed the appointment of Sanford Health CEO Bill Gassen to its board, and on April 6, 2026 it filed an 8-K stating its Chief Technology Officer Eli Rosner would be terminated without cause effective April 17, 2026, with oversight of the technology organization moving to EVP, Chief Product and Strategy Officer Sunil Rajasekar.

Key swing factors for HQY include follow-through on the raised fiscal 2027 outlook, sustainability of margin gains, and execution continuity through the technology leadership transition. Investors will also be watching capital return pace and balance-sheet positioning, given the company’s recent emphasis on share repurchases and managing HSA cash repricing risk.